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INTRODUCTION
Over the past decade, the cost of genome-scale sequencing 
(i.e., genome and exome sequencing) has dropped dramati-
cally, which has led to its increased application in clinical and 
research settings.1–3 The generation of genome-wide sequencing 
data enables identification of findings in addition to the variants 
related to the primary reason for sequencing, such as variants in 
genes that are unanticipated (incidental findings) or purpose-
fully sought (secondary findings).4,5 Identification of a patho-
genic variant associated with an increased risk of a significant, 
but preventable, medical outcome affords the opportunity to 
implement interventions that prevent or mitigate future clinical 
manifestations in patients and their at-risk family members.6,7 
Although some genes and associated disorders have a consider-
able evidence base for clinical actionability, the evidence sup-
porting clinical actionability for most genetic disorders varies 
widely. As such, there is a need to develop and implement stan-
dardized, evidence-based methods to characterize the clinical 
actionability of genomic findings.8 These actionability profiles 
of genetic disorders could be used to facilitate decision making 
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Purpose: Genome and exome sequencing can identify variants 
unrelated to the primary goal of sequencing. Detecting pathogenic 
variants associated with an increased risk of a medical disorder 
enables clinical interventions to improve future health outcomes in 
patients and their at-risk relatives. The Clinical Genome Resource, 
or ClinGen, aims to assess clinical actionability of genes and associ-
ated  disorders as part of a larger effort to build a central resource of 
information regarding the clinical relevance of genomic variation for 
use in precision medicine and research.
Methods: We developed a practical, standardized protocol to iden-
tify available evidence and generate qualitative summary reports of 
actionability for disorders and associated genes. We applied a semi-
quantitative metric to score actionability.
Results: We generated summary reports and actionability scores for 
the 56 genes and associated disorders recommended by the Ameri-
can College of Medical Genetics and Genomics for return as second-
ary findings from clinical genome-scale sequencing. We also describe 
the challenges that arose during the development of the protocol that 
highlight important issues in characterizing actionability across a 
range of disorders.
Conclusion: The ClinGen framework for actionability assess-
ment will assist research and clinical communities in making clear, 
 efficient, and consistent determinations of actionability based on 
transparent criteria to guide analysis and reporting of findings from 
clinical genome-scale sequencing.
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regarding which findings should be considered for return of 
results to improve future health outcomes.
The Clinical Genome Resource (ClinGen) is a National 
Institutes of Health–funded consortium of researchers and 
clinicians who are building an open-access and centralized 
resource to define the clinical relevance and actionability of 
genomic variants (http://clinicalgenome.org/).9 The ClinGen 
Actionability Working Group (AWG) is developing practical 
methods to identify genetic disorders with the greatest clini-
cal utility when detected in previously undiagnosed adults. To 
this end, the ClinGen AWG developed a standardized protocol 
to generate evidence-based profiles of clinical actionability of 
genes and associated disorders in the form of summary reports 
and semiquantitative metric (SQM) scores. Although the meth-
ods to identify the evidence base are transparent and standard-
ized, it is noncomprehensive in order to allow for practical and 
efficient consideration of numerous genes and disorders. Thus, 
the summary reports generated by this protocol are focused 
and are intended to provide the initial guidance regarding the 
return of findings to patients based on clinical actionability and 
are not intended to provide guidance on clinical care that would 
occur downstream.
We applied the protocol generated by the ClinGen AWG 
to the list of 56 genes and associated disorders recommended 
by the American College of Medical Genetics and Genomics 
(ACMG) to be returned as secondary findings to patients when 
a pathogenic or likely pathogenic variant is detected during clin-
ical genome-scale sequencing.10,11 We describe the issues that 
arose during the process, many of which have led to improve-
ments in the protocol, scoring metric, and ability to determine 
clinical actionability. These issues illustrate the challenges of 
the task and provide insight for future endeavors involving the 
characterization of clinical actionability. The ClinGen AWG 
framework provides a structure to enable research and clinical 
communities to make clear, streamlined, and consistent deter-
minations of clinical actionability based on transparent criteria 
to guide analysis and reporting of genomic variation.
MATeRIALs AND MeTHODs
The ClinGen AWG developed a protocol for the standardized 
synthesis of available evidence and the generation of consensus 
scores of clinical actionability of genes and associated disorders 
using reproducible and transparent methods (Figure 1). We 
adapted methods to identify relevant evidence and abstract infor-
mation on clinical actionability into summary reports from the 
Evaluation in Genomic Applications in Practice and Prevention 
working group’s protocol to evaluate the evidence base for clini-
cal actionability of incidental or secondary findings.12 The SQM 
scoring methodology was based on a framework generated 
by the North Carolina Clinical Genomic Evaluation by Next-
generation Exome Sequencing project (NCGENES).13
Clinical scenario
The clinical scenario under consideration for this protocol was 
an adult patient who had undergone genome-scale sequencing 
as part of clinical care. This patient had an incidental or second-
ary finding in the form of a known or likely pathogenic vari-
ant causally associated with a genetic disorder unrelated to the 
original indication for sequencing and had not been previously 
diagnosed with this genetic disorder but may have been symp-
tomatic with associated clinical manifestations. For example, 
a pathogenic variant in the HFE gene may be discovered as a 
secondary finding in a patient known to have joint pain and 
who might have undergone treatment for it but had not been 
previously diagnosed with familial hemochromatosis.
Clinical actionability summary reports
For the purposes of protocol development, clinical actionabil-
ity was defined as clinically prescribed interventions specific to 
the genetic disorder under consideration that are effective for 
prevention or delay of clinical disease, lowered clinical burden, 
or improved clinical outcomes in a previously undiagnosed 
adult. Interventions included patient management (e.g., risk-
reducing surgery), surveillance (e.g., colonoscopy), or specific 
circumstances the patient should avoid (e.g., certain types of 
anesthesia). Actionability included interventions to improve 
outcomes for at-risk family members (e.g., increased surveil-
lance). Genetic testing recommendations for at-risk family 
members alone, however, were not considered sufficient to 
meet the criteria for actionability. In addition, for the purposes 
of this protocol, actionability did not include reproductive deci-
sion making.
We assessed the clinical actionability for each topic (i.e., genes 
and associated disorders) in two stages. Stage I was a rapid rule-
out step to eliminate topics from further consideration that did 
not meet the three criteria for minimal clinical actionability: 
(i) the genetic disorder is clinically actionable in an undiag-
nosed adult; (ii) if penetrance or relative risk is known, then 
there is at least one pathogenic variant with moderate pen-
etrance (≥40%) or relative risk (≥2) in any population; and (iii) 
the resulting genetic disorder is a significant health condition 
(stage I dashboard of the summary report template is available 
in the Supplementary Materials online). A single reference 
was sufficient to satisfy any of the stage I criteria, so an exhaus-
tive literature search was not necessary at this stage. The topic 
automatically proceeded to stage II if all three stage I criteria 
were met. If a topic did not meet stage I criteria, then the AWG 
could decide by consensus to make an exception and move the 
topic to stage II. No further action was taken if a topic did not 
meet stage I criteria and was not recommended for exception 
by the AWG.
The purpose of stage II was to document and synthesize key 
evidence related to the clinical actionability of a pathogenic 
genomic finding (Table 1). The AWG Knowledge Synthesis Team 
identified the most current literature on clinical actionability 
for a given topic by using the standardized search methods out-
lined by Goddard et al.12 Briefly, online resources (such as Online 
Mendelian Inheritance in Man (OMIM) (http://www.ncbi.nlm.
nih.gov/omim), GeneReviews (http://www.ncbi.nlm.nih.gov/
books/NBK1116/), OrphaNet (http://www.orpha.net), PubMed 
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(http://www.ncbi.nlm.nih.gov/pubmed), and the National 
Guideline Clearinghouse (http://www.guideline.gov/)) were tar-
geted and filtered to identify clinical guidelines and secondary 
literature, such as systematic reviews and meta-analyses. Primary 
literature and narrative reviews were not considered. This search 
method was transparent, reproducible, and appropriate for the 
current application, but it was limited in scope for efficiency and 
practicality and thus was not comprehensive. Each reference iden-
tified during the search was examined for relevance to actionabil-
ity in the context of the clinical scenario. Any references deemed 
irrelevant were excluded.
Once we had identified all relevant references, each refer-
ence was assigned a quality tier based on predefined criteria 
(Table  1). Information from the highest-tiered source was 
abstracted and condensed into a summary report with stan-
dardized information documented for each topic (the summary 
report template is available in the Supplementary Materials 
online). The information abstracted addressed five of the most 
important aspects of clinical actionability: (i) the nature of the 
threat to health for an individual carrying a pathogenic allele of 
the given gene or genes; (ii) the effectiveness of available inter-
ventions for preventing or mitigating harm; (iii) the likelihood 
Figure 1 ClinGen Actionability Working Group workflow. AWG, Actionability Working Group; KST, Knowledge Synthesis Team.
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Table 1 Knowledge Synthesis Team’s stage II methods for generating summary reports
Systematic identification of sources
Clinical practice guidelines, systematic reviews, and meta-analyses
OMIM, GeneReviews, and OrphaNet entries
Clinical Utility Gene Cards
Excluded: Narrative reviews and single-study research papers
Determination of relevance
Relevant references provide information on actionability in an adult who has not been diagnosed with the genetic condition, although they may be 
symptomatic for the clinical manifestations associated with the genetic condition
Actionability is defined as interventions or treatments that might lead to disease prevention or delayed onset, lowered clinical burden, or improved 
clinical outcomes
Tier ratings of relevant sources
Tier 1:  evidence from a systematic review, a meta-analysis clearly based on a systematic review, or a clinical practice guideline clearly based on a 
systematic review
Tier 2:  evidence from clinical practice guidelines or broad-based expert consensus with some level of evidence review, but using unclear methods or 
sources that were not systematically identified
Tier 3:  evidence from another source with nonsystematic review of evidence (e.g., GeneReviews, OrphaNet, and Clinical Utility Gene Cards, or opinion of 
up to 4 experts that provides guidance) with primary literature cited
Tier 4:  evidence from another source with nonsystematic review of evidence (e.g., GeneReviews, OrphaNet, and Clinical Utility Gene Cards, or opinion of 
up to four experts that provides guidance) with no citations to primary data sources
Tier 5: evidence from a nonsystematically identified source (e.g., nominated by an AWG member for inclusion)
Data abstraction
Evidence with the highest tier is abstracted for five aspects of clinical actionability:
1. What is the nature of the threat to health for an individual carrying a pathogenic allele of the given gene?
2. How effective are interventions for preventing harm?
3. What is the chance that this threat will materialize?
4. How acceptable are the interventions in terms of the burdens or risks placed on the individual?
5. Would the underlying risk or condition escape detection prior to harm in the setting of recommended care?
AWG, Actionability Working Group.
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that the threat will materialize (i.e., the penetrance of that trait 
attributable to the variant); (iv) the nature of the intervention in 
terms of the burdens or risks placed on the individual with the 
genomic finding; and (v) the chance that the underlying risk or 
disorder could escape detection prior to harm in the setting of 
standard care. Information for this last domain was abstracted 
only for the summary reports and was not incorporated into 
the scores for clinical actionability.
AWG review of summary reports
Although the methods for identifying evidence on clini-
cal actionability facilitate the transparency and feasibility of 
addressing a large number of topics, these reports do not reflect 
a comprehensive overview of all primary literature, and they 
thus limit our ability to inform all aspects of clinical actionabil-
ity. As such, discrepancies may emerge between the summary 
reports and primary study publications or widely accepted 
expert clinical practice regarding clinical actionability of a par-
ticular topic. To address this issue, AWG members reviewed 
preliminary summary reports and nominated additional 
sources for consideration, such as primary literature, when 
applicable (tier 5, Table 1). This important contribution made 
the process more comprehensive and enabled the scoring of all 
domains of clinical actionability.
semiquantitative scoring metric application
Selection of outcome–intervention sets for scoring. Some 
genetic conditions are associated with a variety of distinct 
clinical outcomes that vary in terms of severity, actionability, 
or likelihood. Likewise, interventions vary with regard to 
effectiveness, risk, or burden. For example, hereditary breast 
and ovarian cancer syndrome (HBOC) is associated with 
breast and ovarian cancers, which are distinct in likelihood 
and actionability, and the interventions for these outcomes 
vary in effectiveness, risk, and burden (e.g., surveillance vs. 
risk-reducing surgery). Thus, assessing all possible outcomes 
and interventions simultaneously to generate a single clinical 
actionability score would be misleading. The AWG addressed 
this issue by considering specific outcome–intervention pairs 
within the defined clinical scenario and scoring each pair 
separately for clinical actionability. The outcomes selected for 
scoring referred to significant and likely actionable clinical 
manifestations of the genetic disorder, which were then paired 
with relevant interventions. In the example of HBOC, three 
outcome and intervention pairs were identified for scoring: 
(i) breast cancer and surveillance; (ii) breast cancer and risk-
reducing surgery; and (iii) ovarian cancer and risk-reducing 
surgery.
Scoring method. Assuming a pathogenic variant in the gene 
or genes under consideration, the AWG members applied the 
SQM to the information in the corresponding summary report 
to score each topic for four domains of clinical actionability: 
(i) severity of the outcome; (ii) likelihood of the disease; 
(iii) effectiveness of the intervention; and (iv) nature of the 
intervention in terms of burden and risk to the patient (Table 
2). Each domain was scored from 0 to 3, resulting in a final 
“actionability score” from 0 (least clinically actionable) to 12 
(most clinically actionable). In addition, scorers rated the 
knowledge base regarding the likelihood of the disease and 
the effectiveness of the intervention; this scale ranged from 
substantial evidence (“A”) to poor evidence (“D”) as well as 
nonsystematically identified sources (“E”).
Each topic was independently scored by multiple AWG 
members, and then the scores were discussed among the larger 
AWG. We used consensus for assigning a single actionability 
score to each outcome–intervention pair.
ResULTs
Clinical actionability summary reports and scores
The AWG applied the current protocol to the list of 56 genes 
recommended for return as secondary findings by ACMG.10,11 
Three topics did not pass stage I of the assessment for clinical 
actionability based on evidence identified in the preliminary 
literature search. Two of the three that did not pass stage I, 
retinoblastoma and WT1-related Wilms tumor, were not deter-
mined to be actionable in an undiagnosed adult, and the AWG 
did not make an exception for these topics to proceed to stage 
II. The third disorder that did not pass stage I based on evidence 
in the identified literature, Brugada syndrome, was determined 
to be actionable in an undiagnosed adult and a significant 
medical problem, but it did not meet the criteria for moder-
ate penetrance or relative risk, because only 20–30% of people 
with this syndrome experience syncope and 8–12% have at least 
one cardiac arrest that could cause sudden death.14 However, 
the AWG made an exception for Brugada syndrome to proceed 
to stage II due to the severity of the clinical outcomes. Thus, 
Brugada syndrome and the remaining topics from the 56 genes 
assessed by the AWG (ACMG 56) that passed stage I have com-
pleted the AWG workflow and have been assigned consensus 
scores for clinical actionability (Table 3). These scores indicate 
mid- to high levels of actionability and a variety of available 
evidence to inform clinical actionability with regard to clinical 
interventions and the likelihood of clinical manifestations. The 
summary reports generated by the AWG are available on the 
ClinGen website (www.clinicalgenome.org).
AWG challenges with scoring clinical actionability
The design and application of the protocol to characterize clini-
cal actionability have presented thought-provoking challenges. 
For example, defining the outcomes and interventions for scor-
ing clinical actionability was straightforward for some topics 
(e.g., familial adenomatous polyposis, which is associated with 
colorectal cancer as its major life-threatening manifestation 
that can largely be prevented with colectomy15) but difficult for 
others (e.g., Li–Fraumeni syndrome, a disorder associated with 
a vast array of neoplasms, including breast cancer, colorectal 
cancer, brain tumors, and osteosarcomas16). In the latter case, 
it was difficult to narrow down all potential outcomes and 
interventions for scoring. Some strategies the AWG considered 
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included scoring only outcome–intervention sets for the most 
common outcomes or the most severe outcomes. In addition, 
interventions selected for scoring and their associated risk or 
burdens were often highly contextual and thus difficult to score. 
For example, for a woman with a pathogenic BRCA1 variant, 
the risk and burden of a recommended oophorectomy may be 
greater during childbearing years than during postmenopausal 
years. One potential option would be to generate scores across 
different contexts. In the example of BRCA1 and oophorec-
tomy, this approach could entail generating scores by age (e.g., 
25, 40, and 55 years); both the penetrance and burden of the 
intervention could vary significantly.
Assessment of the effectiveness of an intervention has been 
discussed extensively among the AWG. Some interventions 
overtly prevent an outcome, whereas others aim to minimize 
morbidity through early detection. For example, in women 
with BRCA1 and BRCA2 variants associated with HBOC, 
risk-reducing surgeries (i.e., prophylactic mastectomy and 
oophorectomy) are effective for reducing breast and ovarian 
cancer incidence, whereas breast cancer surveillance, such as 
mammography and magnetic resonance imaging (MRI), are 
designed for early disease detection to reduce morbidity.17 
Because the AWG pursues both types of interventions, they 
are scored separately for actionability and the surveillance 
option is judged by its effectiveness to ultimately prevent a poor 
clinical outcome rather than its effectiveness in detecting can-
cer. Similarly, patients with neurofibromatosis type 2, who are 
at high risk for bilateral vestibular schwannomas, are advised 
to undergo regular MRI surveillance.18,19 MRI surveillance, of 
course, does not directly prevent vestibular schwannomas, but 
it is effective in triggering and directing distal and definitive 
clinical treatment (e.g., tumor excision). Therefore, when the 
AWG assessed clinical actionability, the effectiveness of both 
the proximal and distal effects of the intervention were con-
sidered. Thus, the concept of effectiveness with regard to our 
protocol could be fluid across outcomes and interventions and 
include both reduction in mortality and decreased or delayed 
morbidity.
The AWG also considered circumstances to avoid while 
evaluating the clinical actionability of a gene–disease pair. For 
example, patients with the vascular form of Ehlers–Danlos 
syndrome should avoid elective surgery and other invasive 
procedures (e.g., arteriograms) because of the increased risk of 
vascular rupture or organ perforation.20 The difficulty in scor-
ing the effectiveness of such an intervention lies in the fact that 
avoiding the circumstance does not improve the health of the 
patient per se but not avoiding the circumstance can worsen it.
The protocol developed by the AWG relied heavily on pub-
lished practice guidelines, with priority given to guidance based 
on evidence review. Paradoxically, many published guidelines 
Table 2 Semiquantitative metric to score clinical actionability
Domain scores
severity: what is the nature of the threat to health to an individual carrying a 
clearly deleterious allele in this gene?
3 = Reasonable possibility of sudden death
2 = Reasonable possibility of death or major morbidity
1 = Modest morbidity
0 = Minimal or no morbidity
Likelihood of disease: what is the chance that a serious outcome will 
materialize given a deleterious variant (akin to penetrance)?
3 = >40% chance
2 = 5–39% chance
1 = 1–4% chance
0 = <1% chance
effectiveness of specific interventions: how effective is the selected, specific 
intervention for preventing or significantly diminishing the risk of harm?
3 = Highly effective
2 = Moderately effective
1 = Minimally effective
0 = Controversial or unknown effectiveness
IN = Ineffective/no interventiona
Nature of intervention: how risky, medically burdensome, or intensive is a 
given intervention?
3 = Low risk, or medically acceptable and low-intensity interventions
2 = Moderate risk, moderately acceptable or intensive interventions
1 = Greater risk, less acceptable and substantial interventions
0 = High risk, poorly acceptable or intensive interventions
state of the knowledge base: what is the level of evidence? A = Substantial evidence, or evidence from a high tier (tier 1)
B = Moderate evidence, or evidence from a moderate tier (tier 2)
C = Minimal evidence, or evidence from a lower tier (tier 3 or 4)
D = Poor evidence, or evidence not provided in the report
E = Evidence based on expert contributions (tier 5)
aDo not score the remaining categories.
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Table 3 Clinical actionability scores for the ACMG 56a
Disorder Gene(s) Outcome/intervention pair severity Likelihood effectiveness
Nature of 
intervention
Total 
score
Marfan syndrome FBN1 Aortic dilation progression/ 
β-blockers
3 3C 3A 3 12CA
Clinically significant aortic aneurysm/
surveillance
3 3C 3B 3 12CB
Loeys–Dietz syndrome TGFBR1, TGFBR2, 
SMAD3
Clinically significant aortic aneurysm/
surveillance
3 3C 3C 3 12CC
Aortic dilation progression/ 
β-blockers
3 3C 3C 3 12CC
Familial thoracic aortic 
aneurysms and dissections
FBN1, TGFBR1, 
TGFBR2, SMAD3, 
ACTA2, MYLK, 
MYH11
Clinically significant aortic aneurysm/
surveillance
3 2Db 3Cb 3 11DC
Aortic dilation progression/ 
β-blockers
3 2D 3Cb 3 11DC
Familial 
hypercholesterolemia 
(heterozygous form)
LDLR, APOB, PCSK9 High cholesterol/statins 2 3C 3A 3 11CA
Familial 
hypercholesterolemia 
(homozygous form)
LDLR, APOB, PCSK9 High cholesterol/statins 2 3C 3A 3 11CA
High cholesterol/low-density 
lipoprotein aphaeresis
2 3C 3B 2 10CB
von Hippel–Lindau 
syndrome
VHL Pheochromocytoma/surveillance 2 3C 2B 3 10CB
Renal cell carcinoma/surveillance 2 3C 3C 3 11CC
Dilated cardiomyopathy TNNT2, LMNA Sudden cardiac death/surveillance 
and pharmacology
3 3C 2Cb 3 11CC
Sudden cardiac death/
pharmacotherapy
3 3C 2B 2 10CB
Heart failure/surveillance and 
angiotensin-converting enzyme 
inhibitors
2 3C 2B 3 10CB
Multiple endocrine 
neoplasia type 2B
RET Pheochromocytoma/biochemical 
surveillance
2 3C 3B 3 11CB
Medullary thyroid carcinoma/ 
risk-reducing surgery
2 3C 3A 1 9CA
Multiple endocrine 
neoplasia type 2A; familial 
medullary thyroid cancer
RET Morbidity or mortality from 
pheochromocytoma/biochemical 
surveillance
2 3C 3B 3 11CB
Medullary thyroid cancer/
prophylactic thyroidectomy
2 3C 3A 1 9CA
Morbidity or mortality from 
hyperparathyroidism/biochemical 
surveillance
1 2C 3B 3 9CB
Peutz–Jeghers syndrome STK11 Colorectal cancer/surveillance 2 3A 3B 3 11AB
Breast cancer/surveillance 2 3C 2A 3 10CA
Breast cancer/chemoprevention 2 3C 2A 2 9CA
Breast cancer/risk-reducing surgery 2 3C 3B 1 9CB
Ovarian cancer/risk-reducing surgery 2 2A 3B 1 8AB
Ovarian cancer/surveillance 2 2A 0B 3 7AB
ACMG, American College of Medical Genetics and Genomics; AWG, Actionability Working Group.
aTable does not include two disorders from the original ACMG 56 list that did not pass stage I: retinoblastoma and WT1-related Wilms tumor. bScores for which the score or 
level of evidence assigned by AWG differs from the summary report.
Table 3 Continued on next page
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Neurofibromatosis, type 2 NF2 Vestibular schwannoma/surveillance 2 3Bb 2B 3 10BB
Ehlers–Danlos syndrome, 
type 4
COL3A1 Vascular or organ rupture or 
perforation/avoidance of invasive 
procedures
3 3C 2A 2 10CA
MYH-associated polyposis MUTYH Colorectal cancer/surveillance and 
colectomy
2 3C 3B 2 10CB
Malignant hyperthermia 
susceptibility
RYR1, CACNA1S Morbidity from malignant 
hyperthermia event/avoidance of 
triggering anesthetics
2 2D 3B 3 10DB
Catecholaminergic 
polymorphic ventricular 
tachycardia
RYR2 Sudden cardiac death/β-blockers 3 2Eb 2B 3 10EB
Multiple endocrine 
neoplasia type 1
MEN1 Morbidity from other 
neuroendocrine tumors/biochemical 
surveillance
2 3C 2B 3 10CB
Morbidity from parathyroid tumors/
biochemical surveillance
1 3C 3B 3 10CB
Morbidity from other 
neuroendocrine tumors/imaging 
surveillance
2 3C 2B 2 9CB
PTEN hamartoma tumor 
syndrome
PTEN Breast cancer/surveillance 2 3C 2B 3 10CB
Thyroid cancer/thyroid 
ultrasonography
2 2C 2B 3 9CB
Hereditary paraganglioma-
pheochromocytoma 
syndrome
SDHD Paraganglioma development/
surveillance
2 3C 2C 3 10CC
SDHB Paraganglioma development/
surveillance
2 3C 2C 3 10CC
SDHAF2 Paraganglioma development/
surveillance
2 2C 2C 3 9CC
SDHC Paraganglioma development/
surveillance
2 2C 2C 3 9CC
Hereditary breast and 
ovarian cancer syndrome
BRCA1 Breast cancer/surveillance 2 3A 2A 3 10AA
Breast cancer/risk-reducing surgery 2 3A 3A 1 9AA
Ovarian cancer/risk-reducing surgery 2 2A 3A 1 8AA
BRCA2 Breast cancer/surveillance 2 3A 2A 3 10AA
Breast cancer/risk-reducing surgery 2 3A 3A 1 9AA
Ovarian cancer/risk-reducing surgery 2 2A 3A 1 8AA
Lynch syndrome MLH1, MSH2, 
MSH6, PMS2
Colorectal cancer/surveillance 2 3Ab 3A 2 10AA
Endometrial cancer/surveillance 2 3Ab 1A 2 8AA
Endometrial cancer/risk-reducing 
surgery
2 3Ab 3B 1 9AB
Romano–Ward long QT 
syndrome
KCNQ1, KCNH2 Sudden cardiac death/β-blockers 3 2C 2B 3 10CB
Sudden cardiac death/implantable 
cardioverter defibrillator
3 2C 2A 2 9CA
SCN5A Sudden cardiac death/β-blockers 3 2C 0D 3 8CD
Sudden cardiac death/implantable 
cardioverter defibrillator
3 2C 2A 2 9CA
Table 3 Continued
Disorder Gene(s) Outcome/intervention pair severity Likelihood effectiveness
Nature of 
intervention
Total 
score
ACMG, American College of Medical Genetics and Genomics; AWG, Actionability Working Group.
aTable does not include two disorders from the original ACMG 56 list that did not pass stage I: retinoblastoma and WT1-related Wilms tumor. bScores for which the score or 
level of evidence assigned by AWG differs from the summary report.
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Li–Fraumeni syndrome TP53 Colorectal cancer/surveillance 2 3C 3Cb 2 10CC
Breast cancer/surveillance 2 3C 2Bb 3 10CC
Breast cancer/avoidance of 
radiotherapy
2 3C 2Bb 3 10CC
Ovarian cancer/avoidance of 
radiotherapy
2 3C 2Cb 3 10CC
Colorectal cancer/avoidance of 
radiotherapy
2 3C 2Cb 3 10CC
Sarcomas/avoidance of radiotherapy 2 3C 2Cb 3 10CC
Central nervous system tumors/
avoidance of radiotherapy
2 3C 2Cb 3 10CC
Adrenocortical tumors/avoidance of 
radiotherapy
2 3C 2Cb 3 10CC
Sarcomas/surveillance 2 3C 2E 3 10CE
Adrenocortical tumors/surveillance 2 3C 2E 3 10CE
Breast cancer/risk-reducing surgery 2 3C 3Cb 1 9CC
Ovarian cancer/risk-reducing surgery 2 3C 3Cb 1 9CC
Colorectal cancer/risk-reducing 
surgery
2 3C 3Cb 1 9CC
Central nervous system tumors/
surveillance
2 3C 1Cb 3 9CC
Ovarian cancer/surveillance 2 3C 0Cb 3 8CC
Tuberous sclerosis complex TSC1 Morbidity and mortality from 
masses/imaging
2 3E 2B 3 10EB
TSC2 Subependymal giant cell 
astrocytoma development/mTOR 
inhibitor treatment
2 2E 2B 2 8EB
Pulmonary 
lymphangioleiomyomatosis 
development/mTOR inhibitor 
treatment
2 2E 2B 2 8EB
Brugada syndrome SCN5A Sudden cardiac death/implantable 
cardioverter defibrillator
3 2C 2B 2 9CB
Arrythmogenic right-
ventricular cardiomyopathy
PKP2, DSP, DSC2, 
TMEM43, DSG2
Sudden cardiac death/implantable 
cardioverter defibrillator
3 2C 2A 2 9CA
Sudden cardiac death/anti-
arrhythmic therapy
3 2C 1C 2 8CC
Hypertrophic 
cardiomyopathy
MYBPC3, MYH7, 
TNNT2, TNNI3, 
TPM1, MYL3, ACTC1, 
PRKAG2, MYL2
Sudden cardiac death/implantable 
cardioverter defibrillator
3 2E 2B 2 9EB
Familial adenomatous 
polyposis
APC Colorectal cancer/surveillance and 
colectomy
2 3Ab 2B 1 8AB
Fabry disease GLA End-stage organ disease/enzyme 
replacement therapy (classic, males)
2 3E 1A 2 8EA
End-stage organ disease/enzyme 
replacement therapy (late-onset, 
males)
2 3E 1A 2 8EA
End-stage organ disease/enzyme 
replacement therapy (females)
2 3E 1A 2 8EA
Stroke prevention/aspirin (classic, 
males)
2 2E 0B 3 7EB
Stroke prevention/aspirin (late-onset, 
males)
2 2E 0B 3 7EB
Stroke prevention/aspirin (females) 2 2E 0B 3 7EB
ACMG, American College of Medical Genetics and Genomics; AWG, Actionability Working Group.
aTable does not include two disorders from the original ACMG 56 list that did not pass stage I: retinoblastoma and WT1-related Wilms tumor. bScores for which the score or 
level of evidence assigned by AWG differs from the summary report.
Table 3 Continued
Disorder Gene(s) Outcome/intervention pair severity Likelihood effectiveness
Nature of 
intervention
Total 
score
GeNeTICs in MeDICINe  |  Volume 18  |  Number 12  |  December 2016
1266
HUNTER et al  |  Assessing clinical actionabilityOriginal research article
do not provide evidence summaries for their recommendations. 
Thus, the actual effectiveness of a recommended intervention is 
sometimes unclear or unknown. For example, a recommendation 
for patients with Fabry disease is to take aspirin or other plate-
let-inhibiting agents to reduce their risk of stroke, although the 
effectiveness of this intervention was not described in the origi-
nal source.21 AWG members were not comfortable scoring the 
effectiveness of this recommendation without evidence of stroke 
reduction for these patients, and the absence of supporting evi-
dence limited the ability to measure effectiveness. This issue may 
eventually be addressed by new guideline criteria submitted to the 
National Guidelines Clearinghouse (http://www.guideline.gov/
about/inclusion-criteria.aspx) as well as the Institute of Medicine’s 
recommendations for developing trustworthy guidelines.22 These 
criteria would require guidelines to be transparent regarding the 
methods used, to be based on a systematic review of evidence 
(where it exists), and to provide an assessment of the benefits and 
harms of recommended care and alternative care options.
For rarer disorders, guidelines often base recommendations 
on evidence extrapolated from more common and related 
disorders. For example, evidence of the effectiveness of breast 
surveillance and risk-reducing surgery among women with 
BRCA1 and BRCA2 mutations has been used to recommend 
these interventions for women with rarer disorders that also 
increase the risk of breast cancer (e.g., Peutz–Jegher and Li–
Fraumeni syndromes).17 To account for this extrapolation in 
such cases, the AWG adjusted the rating for the knowledge base 
when scoring actionability, such as reducing the score of the 
knowledge base even if the guideline even if the guideline meets 
criteria for a tier 1 or tier 2 reference (Table 2). Similarly, AWG 
members often gave the knowledge base a higher score than 
what the guideline tier warranted if their clinical opinion or 
experience indicated a discrepancy. For example, a tier 3 source 
for the penetrance of colorectal cancer on familial adenoma-
tous polyposis was identified, but the knowledge base for likeli-
hood was scored as an “A” based on discussion by the AWG.
DIsCUssION
The AWG applied a standardized protocol to assess clinical 
actionability to the list of 56 genes recommended by the ACMG 
to return as secondary findings.10,11 As we expected, these dis-
orders had scores at moderate to high levels of actionability. 
However, the actionability scores for different outcome–inter-
vention pairs within genetic disorders varied. For HBOC, for 
example, breast cancer and surveillance had a higher action-
ability score than did ovarian cancer and oophorectomy (10 
and 8, respectively). These scores highlight the nuance of 
generating consensus scores on actionability that account for 
both the effectiveness and nature of the intervention. In the 
HBOC example, the intervention deemed more effective for 
eliminating the harm (i.e., risk-reducing surgery) received a 
lower actionability score than the intervention deemed less 
effective for eliminating the harm (i.e., breast cancer surveil-
lance) that was also less burdensome and invasive. In addition, 
although some disorders have substantial evidence for clinical 
actionability (e.g., HBOC), others have limited evidence (e.g., 
hereditary paraganglioma–pheochromocytoma syndrome).
The SQM, which enabled us to balance qualitative and quan-
titative scoring, was useful because it provided a predefined 
range of scores rather than the presence or absence of poten-
tial clinical actionability. This approach also allowed for scorers’ 
subjectivity, a necessary criterion for any metric that must deal 
with issues that, like actionability, are not entirely quantifiable 
and incorporate subjective perceptions. The fact that the AWG 
scoring framework and the Multi-Criteria Decision Analysis 
developed by EVIDEM23 have many parallels and were devel-
oped independently reinforces the applicability of the scoring 
approach used by ClinGen.
The actionability scores generated by the AWG protocol 
should inform ongoing efforts by the ACMG and other groups 
to maintain and update lists to guide return of secondary or 
incidental findings. In addition, external stakeholders can apply 
the scores to prioritize genes for reporting incidental or sec-
ondary findings or for other purposes for which actionability is 
important. For example, the range of scores generated across a 
variety of genes and associated disorders could be used to iden-
tify a threshold indicative of a certain level of actionability to 
warrant the return of findings to patients. In addition, the end 
user could decide a priori whether a single outcome and the 
associated actionable intervention for a disorder and associ-
ated gene or genes are sufficient for the return of the finding. 
Actionability scoring methods may also inform other contexts 
in which actionability is important, such as primary screening.
The limitations of the AWG protocol are worth noting. For 
example, the recommendations added to the summary reports 
were deliberately not comprehensive because focusing on evi-
dence-based and expert-based clinical resources and secondary 
literature made it possible to generate brief reports in a practi-
cal amount of time and in a consistent format. Thus, the proto-
col is not designed to identify all available evidence regarding 
actionability for a particular topic. However, this process iden-
tified gaps in synthesized knowledge and the need for future 
research and clinical translation to improve the knowledge base 
for clinical actionability of genetic disorders. It also highlights 
the need for evidence-based guidelines, as recommended by 
the National Academy of Medicine (formerly the Institute of 
Medicine).22 This would provide access to evidence summaries 
supporting clinical recommendations to better describe the 
effectiveness of clinical interventions, an important aspect of 
clinical actionability.
The current protocol was limited in scope and did not 
address certain patient-specific factors that are important to 
clinical care, such as personal utility, patient perspectives on 
the burden of interventions, or how the risks of outcomes and 
burdens of interventions vary with certain patient character-
istics (e.g., age). In addition, the current protocol is limited to 
genetic disorders with clinical actionability among adults and 
does not address only childhood-onset disorders. Although the 
limited scope of the protocol was based on feasibility, it can be 
expanded in future iterations.
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The SQM developed for this protocol enabled us to assign a 
range of scores rather than the presence or absence of clinical 
actionability. It should be recognized that the scoring assign-
ments for various aspects of actionability necessarily have an 
inherently subjective component (Table 2). For example, a 
disorder with the potential for sudden death (e.g., Brugada 
syndrome) was assigned a higher score for severity than a dis-
order that may lead to a more delayed mortality (e.g., Lynch 
syndrome). The rationale for this was that medical events that 
could lead to sudden death (e.g., aortic aneurysm) may have 
little or no clinical warning or window of time after onset to 
prevent death. Thus, for these conditions, a higher score was 
assigned to account for the arguably greater need to identify 
patients early in order to implement preventative interven-
tions. In addition, a more clinically invasive intervention (e.g., 
prophylactic mastectomy) was assigned a lower score for the 
nature of the intervention than a less invasive intervention 
(e.g., chemoprevention). Although some may argue that the 
invasive nature of the intervention may not make a condition 
more or less actionable, we predetermined that our assessment 
of clinical actionability should account for the risk and burden 
to the patient. Overall, it is important to note that assessments 
of issues such as actionability are meant to provide a starting 
point for discussion.
Generation of the summary reports for clinical actionability 
of additional genetic disorders is ongoing. Advances in health 
care will provide evidence regarding clinical actionability, such 
as new or more effective interventions. In addition, our under-
standing of penetrance, phenotypes, and mutational prevalence 
of many genes and associated disorders is likely to change. Our 
knowledge is currently derived, for the most part, from popu-
lations accrued through biased ascertainment due to clinical 
manifestations or prior diagnosis. Study designs that can reduce 
this ascertainment bias will improve estimates of the prevalence 
and penetrance of genetic disease. Efforts to expand this proto-
col will probably include plans to ensure that summary reports 
stay up to date and remain a reliable resource.
In summary, the AWG protocol provides a structured, trans-
parent framework for summary reviews of evidence regarding 
the clinical actionability of genomic variation that could be 
used in a variety of contexts. The ClinGen AWG framework 
provides needed support to the research and clinical commu-
nities in general for making clear, streamlined, and consistent 
determinations of clinical actionability based on transpar-
ent criteria to guide the analysis and reporting of variations 
detected in genome-scale sequencing.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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